Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO

Cue Biopharma, Inc.

License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.
Concurrent private placement raises ~$28M net via pre-funded warrants and warrants at $11.00/unit to accredited investors including new CEO.
New CEO Dr. Shao-Lee Lin appointed; participates in the private placement.
Ascendant receives pre-funded warrants for 551,724 shares at $0.001; total potential dilution from warrants exceeds 4.6M shares.
Company to seek stockholder approval for share issuances under Nasdaq rules; special meeting within 90 days.

item 1.01item 3.02item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.